mTORC1 Inhibition Corrects Neurodevelopmental and Synaptic Alterations in a Human Stem Cell Model of Tuberous Sclerosis

Graphical Abstract

Highlights

- TSC2 deletion causes gene-dosage-dependent mTORC1 hyperactivity in neurodevelopment
- TSC2 deletion causes alterations in pathways and genes associated with autism
- TSC2+/− and TSC2−/− human neurons show stage-specific cellular and synaptic defects
- mTORC1 inhibition corrects synaptic defects independently of early neurodevelopment

Authors

Veronica Costa, Stefan Aigner, Mirko Vukcevic, ..., Anirvan Ghosh, Josef Bischofberger, Ravi Jagasia

Correspondence

veronica.costa@roche.com (V.C.), ravi.jagasia@roche.com (R.J.)

In Brief

The neurodevelopmental disorder tuberous sclerosis is caused by loss of TSC1/2, negative regulators of mTORC1. Combining genome editing technology and human stem cell differentiation, Costa et al. characterize stage-specific molecular, cellular, and synaptic alterations in neurons with TSC2 deletion and show that mTORC1 inhibition corrects defects in synaptic function independently of early neurodevelopmental abnormalities.
mTORC1 Inhibition Corrects Neurodevelopmental and Synaptic Alterations in a Human Stem Cell Model of Tuberous Sclerosis

Veronica Costa, 1,8,* Stefan Aigner, 1,8,9 Mirko Vukcevic, 5,8 Evelyn Sauter, 1,10 Katharina Behr, 5 Martin Ebeling, 5 Tom Dunkley, 2 Arno Friedlein, 2 Sannah Zoffmann, 3 Laurie Chicha-Gaudimier, 4 Anna Kiialainen, 2 Paolo Piraino, 6 Marc Bedoucha, 1 Martin Graf, 3 Sebastian Jessberger, 7 Anirvan Ghosh, 1 Joseph Bischofberger, 5 and Ravi Jagasia 1,*

1 Roche Pharmaceutical Research and Early Development, Neuroscience Ophthalmology and Rare Diseases Discovery & Translational Area, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
2 Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
3 Roche Pharmaceutical Research and Early Development, Therapeutic Modalities, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland
4 Department of Neurosurgery, Universitätsklinikum der Universität Basel, ZBL 20 Hebelstrasse, 4031 Basel, Switzerland
5 Department of Biomedicine, University of Basel, Pestalozzistrasse 20, 4056 Basel, Switzerland
6 Pvalue Research SRL, 29015 Castel San Giovanni, Italy
7 Brain Research Institute, Faculty of Medicine and Science, University of Zurich, 8057 Zurich, Switzerland
8 Co-first author
9 Present address: Department of Cellular and Molecular Medicine, School of Medicine, University of California, San Diego, La Jolla, CA 92039, USA
10 Present address: Center for Regenerative Therapies Dresden, Technische Universität Dresden, 01307 Dresden, Germany
*Correspondence: veronica.costa@roche.com (V.C.), ravi.jagasia@roche.com (R.J.)

http://dx.doi.org/10.1016/j.celrep.2016.02.090

SUMMARY

Hyperfunction of the mTORC1 pathway has been associated with idiopathic and syndromic forms of autism spectrum disorder (ASD), including tuberous sclerosis, caused by loss of either TSC1 or TSC2. It remains largely unknown how developmental processes and biochemical signaling affected by mTORC1 dysregulation contribute to human neuronal dysfunction. Here, we have characterized multiple stages of neurogenesis and synapse formation in human neurons derived from TSC2-deleted pluripotent stem cells. Homozygous TSC2 deletion causes severe developmental abnormalities that recapitulate pathological hallmarks of cortical malformations in patients. Both TSC2+/− and TSC2−/− neurons display altered synaptic transmission paralleled by molecular changes in pathways associated with autism, suggesting the convergence of pathological mechanisms in ASD. Pharmacological inhibition of mTORC1 corrects developmental abnormalities and synaptic dysfunction during independent developmental stages. Our results uncouple stage-specific roles of mTORC1 in human neuronal development and contribute to a better understanding of the onset of neuronal pathophysiology in tuberous sclerosis.

INTRODUCTION

Increased activity of the mammalian target of rapamycin complex 1 (mTORC1) pathway has been implicated in autism spectrum disorder (ASD) and related neurodevelopmental disorders. Indeed, several monogenic disorders associated with a high rate of autism are caused by mutations in negative regulators of the pathway (Bourgeron, 2009), and mTORC1 overactivation has been detected in temporal lobe of patients with idiopathic ASD (Tang et al., 2014). Moreover, alterations in processes downstream of mTORC1 recapitulate ASD-like behavioral abnormalities and cellular pathology in mice (Santini et al., 2013; Gkogkas et al., 2013; Tang et al., 2014). Thus, a better understanding of the molecular and cellular consequences of mTORC1 hyperfunction might help to identify novel targets for therapeutic intervention.

Tuberous sclerosis (TSC) is a severe multisystem disorder that presents with complex neuropsychiatric symptoms including autism, intellectual disability, and epilepsy (Crino et al., 2006; Rosser et al., 2006). Neuroanatomical abnormalities include formation of cortical tubers, which are disorganized regions of the cortex characterized by the presence of dysplastic neurons with immature electrophysiological properties (Cepeda et al., 2012). The disease is caused by heterozygous loss-of-function mutations in the genes coding for TSC1 or TSC2. Loss of heterozygosity due to somatic mutations of the functional allele has been detected in hamartomas, while its role in tuber formation remains controversial (Henske et al., 1997; Chan et al., 2004; Crino et al., 2010; Qin et al., 2010). TSC1 and TSC2 form a
Deletion of TSC1/2 in animal models affects a wide range of neuronal processes, and inhibition of mTORC1 corrects specific cellular, neuroanatomical, and neurological phenotypes (Melikie et al., 2007, 2008; Magri et al., 2011; Bateup et al., 2013; Tavazoie et al., 2005). The direct cellular and synaptic consequences of TSC2 deletion in human neurons are unknown. Specifically, it is still unclear how increased TSC-mTORC1 pathway activity precipitates the onset of human neuronal dysfunction, how it alters multiple neurodevelopmental stages, and if and when phenotypes can be reversed.

Here, we used genome-engineered TSC2+/− and TSC2−/− human pluripotent stem cells to recapitulate the heterozygous loss of function underlying the disorder and study the effect of complete loss of TSC2 in neuronal development, respectively. Combining a neuronal differentiation protocol and molecular, cellular, and electrophysiological analyses, our results reveal the effects of alterations of the TSC2-mTORC1 pathway on human neurodevelopment and synaptic physiology.

RESULTS

Generation of an Allelic Series of TSC2 Deleted Human Embryonic Stem Cell Lines

Zinc-finger nuclease-mediated targeted gene disruption was used to generate heterozygous and homozygous deletions of TSC2 in the well-characterized SA001 human embryonic stem cell (hESC) line (Englund et al., 2010), which we have previously used to study neuronal maturation (Dunkley et al., 2015). We generated an isogenic allelic series of TSC2 deletions by inserting a neomycin selection cassette into one (TSC2+/−) or both (TSC2−/−) alleles or into the AAVS1 safe harbor locus (TSC2−/+)(Figure 1A). Correct gene targeting was established by genomic PCR amplification across the disruption cassette (Figures S1A and S1B), and absence of additional genomic integrations was confirmed by targeted locus amplification (de Vree et al., 2014) (Figure S1C). Gene targeting resulted in decreased TSC2 protein levels in heterozygous lines and absence of the protein in homozygous clones (Figure 1B). To determine whether TSC2 mutation affected mTORC1 function in hESCs, we monitored phosphorylation levels of the downstream substrate 40S ribosomal protein S6 (RPS6) and found increased phosphorylation in TSC2−/−, but not TSC2+/−, lines (Figure S1D). We observed no differences in hESC colony morphology (Figures 1C and S1E), proliferation, pluripotency, or spontaneous differentiation capacity (data not shown). These results suggest that TSC2 deletion and mTORC1 hyperfunction do not grossly affect pluripotency of hESCs.

Deletion of TSC2 Causes Abnormal Structural Organization of Neuroectodermal Rosettes

In vivo, Tsc2 ablation leads to embryonic lethality and defective neural tube closure in mouse embryos at E11.5 (Kobayashi et al., 1999). We therefore asked whether deletion of TSC2 alters human neuroectodermal rosette formation, the in vitro correlate of in vivo cortical neuroepithelium development (Shi et al., 2012). We induced neuroectodermal differentiation using a modified dual-SMAD inhibition protocol (Figure S2A; Experimental Procedures). Neuroepithelial progenitors expressed the forebrain rosette neural progenitor markers PLZF, Nestin, Pax6, and SOX1, suggesting efficient differentiation in control and mutant lines (Figures 1E and S2C; data not shown). The typical apicobasal polarity was mostly maintained in rosettes from all genotypes, as the tight junction protein zonula occcludens 1 (ZO1) and M phase nuclei were oriented toward the lumen of the rosettes (Figures 1E and S2C) (Falk et al., 2012; Götz and Huttner, 2005). However, TSC2−/− rosettes were more heterogeneous in size due to formation of enlarged rosettes (Figures 1E, 1F, and S2D). Cell size was comparable across genotypes at this stage, suggesting that enlarged rosette size was likely due to increased cell number (Figure S2E). Importantly, this cellular phenotype correlated with overactivation of the mTORC1 pathway in TSC2−/− lines (Figure 1D). We conclude that biallelic TSC2 deletion causes mTORC1 hyperfunction in neuroectodermal rosettes, which in turn impairs their structural organization.

Deletion of TSC2 Alters Neuronal Proliferation, Differentiation, and Morphology in a Gene-Dosage-Dependent Manner

During early neuroectodermal specification, no alterations were observed in TSC2−/− lines. To investigate whether heterozygous TSC2 loss of function, mimicking the TSC patient genotype, leads to neural dysfunction during later stages of development, we generated neural stem cells (NSCs) that can be differentiated into functional neurons (Figures S2A and S2F–S2J; see Experimental Procedures for details). To model a physiologically relevant neuronal network with excitatory and inhibitory neuronal connectivity, we utilized a protocol that differentiates NSCs to glutamatergic and GABAergic neurons (HuC/D± cells, 50.9±3.2%; GABA+/HuC/D± cells, 11.3±5.8% at day 28 of differentiation; Figures 2A, S2A, and S2B) (Dunkley et al., 2015).

TSC2 mutant lines showed early neuronal alterations. At day 14 of differentiation, TSC2−/− showed a ~55% reduction in the number of postmitotic (HuC/D+) neurons. The phenotype was less pronounced (~26% reduction) and transient in TSC2−/+ lines (Figures 2B, 2C, and S3G). TSC2−/− cells exhibited reduced expression of neuronal progenitor markers and aberrant proliferation; Figures 2A, S2A, and S2B) (Dunkley et al., 2015).
maturation and synapse formation. Intriguingly, we observed dysregulation of the chloride transporters NKCC1 (SLC12A2) and KCC2 (SLC12A5), which affect neuronal excitability in response to GABA, are dynamically regulated during brain development and are altered in cortical tubers from TSC patients (Figures 2E and S3F) (Ben-Ari et al., 2012; Jagasia et al., 2009; Talos et al., 2012). At day 14 of differentiation, TSC2−/− (but not TSC2+/−) neurons showed increased soma size, recapitulating what is observed in cortical tubers and attributed to mTORC1 hyperfunction (Figure 2B, right; and Figure 2D) (Ruppe et al., 2014). To assess morphological alterations in mature neurons (Figures S2K and S2N), we analyzed biocytin-filled 6- to 8-week-old neurons (Figure 2F). TSC2−/− neurons exhibited increased dendritic arborization measured by Sholl analysis, increased soma size, and an ~2-fold increase in total dendritic length (Figures 2G, S3H, and S3I). TSC2+/− neurons did not show gross morphological changes. In a correlation analysis, we observed a positive correlation of moderated t statistics values for transcripts and proteins between TSC2+/− and TSC2−/− lines compared to controls at days 14 and 41 of differentiation (r = 0.617 and r = 0.298 for transcripts and r = 0.552 and r = 0.444 for proteins at days 14 and 41, respectively; Figure 2H). Cluster analysis revealed a trend toward downregulation of genes relevant for synaptic transmission in both TSC2+/− and TSC2−/− neurons. The cluster of proteins/transcripts with the largest effect included genes and pathways associated with autism including CNTNAP2, NLG3, and KCC2 (Figure 2I). In addition, we observed in both genotypes downregulation of RBFOX1, a splicing factor reduced in brains from idiopathic ASD patients (Figure S3J) (Fogel et al., 2012, Voineagu et al., 2011). In the aggregate, these data indicate that monoallelic deletion of TSC2 causes persistent dysregulation of ASD-relevant genes that is similar to that observed in TSC2−/− cells but whose extent remains below the threshold required to elicit...
Figure 2. TSC2 Deletion Causes Deficits in Neuronal Proliferation, Differentiation, and Maturation

(A) Neuronal differentiation protocol outline. NSCs, neural stem cells; R, replating. For details, see Experimental Procedures.

(B) Representative confocal images of day 14 differentiated neurons. Confocal z-axis stacks were acquired and reconstructed. Scale bars represent 100 μm (left) and 10 μm (right).

(C and D) Neuronal content (C) and soma size (HuC/D+ area; D) in day 14 differentiated cultures. Experiments were as in (B); n = 4, *p < 0.05. Acquisition and automated quantification performed with Operetta HCS. Data represent mean ± SEM. A and B indicate two clones with the same genotypes.

(E) qPCR quantitation of gene expression levels in day 14 differentiated cultures. Data are normalized to a pool of housekeeping genes and expressed as fold change (log2) relative to TSC2+/+ lines. Data represent mean ± 95% confidence interval, n = 4. All fold changes are statistically significant.

(F) Representative fluorescence images of biocytin-filled day 41–63 differentiated neurons. Confocal images were acquired with Zen software. Scale bar, 50 μm.

(G) Sholl analysis of experiments as in (F). TSC2+/+: n = 6, TSC2+/−: n = 4, TSC2−/−: n = 8. Data represent mean ± SEM.

(legend continued on next page)
most of the early cellular phenotypes seen in the full knockout. In addition, our molecular analysis suggests that TSC2 deletion leads to alterations in synapse biology in both genotypes.

**TSC2 Heterozygous Deletion Leads to mTORC1 Hyperfunction in Differentiating Neuronal Cultures**

To address whether the observed molecular and cellular deficits correlated with alterations in mTOR signaling, we monitored the phosphorylation status of mTORC1 downstream substrates in response to physiologically relevant modulators (insulin-like growth factor [IGF] and brain-derived neurotrophic factor [BDNF]) and known inhibitors (rapamycin and nutrient starvation) of the pathway. As expected, TSC2 protein was reduced to ~50% in TSC2+/− lines and absent in TSC2−/− lines (Figures S4A and S4B). Lines from all genotypes exhibited an IGF1-dependent increase in phosphorylation of the mTORC2 substrate AKT at serine 473 (Sarbassov et al., 2005) in both NSCs (Figures 3A and S4E) and neurons (Figures 3B and S4F). In contrast, BDNF elicited a response only in neurons, consistent with functional maturation of the culture (Figures 3A, 3B, S4C, and S4D). Phosphorylation of mTORC1 targets S6 and eukaryotic translation initiation factor 4E binding protein 1 (4EBP1) showed TSC2 gene-dosage-dependent alterations. TSC2−/− cells showed constitutive activation of mTORC1 as shown by increased phosphorylation of S6 and 4EBP1 even upon withdrawal of growth factors, a condition which silences the pathway in control lines. Furthermore, TSC2−/− lines exhibited a marked reduction of AKT phosphorylation, previously ascribed to mTORC1-dependent negative feedback signaling (Shah and Hunter, 2006, Harrington et al., 2004). Indeed, the reduction was partially reverted upon rapamycin treatment (from ~34% to ~84% of TSC2+/+ at day 0 and from ~12% to ~42% of TSC2+/+ at day 35, in the presence of growth factors without and with rapamycin, respectively; Figures 3A, 3B, and S4H). Surprisingly, although we could not observe gross differential regulation between control and TSC2+/− lines at the NSC stage (Figure 3A), phosphorylation of S6 and 4EBP1 was increased in TSC2−/− lines at day 35 (Figures 3B and S4D; quantification in Figure S4H).

Interestingly, upon differentiation, negative regulators of the mTOR pathway were upregulated in control lines (TSC1 and TSC2, ~3-fold; PTEN, ~10-fold), suggesting a tight regulation of the pathway in neurons (Figures S4A and S4B). In mature neurons, TSC1 protein expression was reduced in TSC2+/+ and TSC2−/− lines (Figures S4 A and S4B). This suggests that the mTORC1 pathway is tightly regulated during neuronal maturation and that an ~50% reduction in TSC2 leads to a molecular phenotype in neurons. Moreover, homozygous deletion of TSC2 leads to constitutive activation of mTORC1 and dysregulation of feedback signaling pathways as observed in cortical tubers (Ruppe et al., 2014).

**mTORC1 Inhibition Corrects Excitability and Synaptogenesis Deficits Independently of Early Neurodevelopmental Alterations**

We next asked if, and at what stage during neuronal differentiation, cellular and electrophysiological phenotypes could be corrected by inhibition of mTORC1. Rapamycin treatment of

---

**Figure 3. Neuronal Maturation Reveals mTORC1 Hyperfunction in TSC2−/− Neurons**

(A) and (B) Proteins (10 μg) from NSCs (A) and day 35 differentiated neurons (B) were analyzed by SDS-PAGE/immunoblotting. Where indicated, cells were treated as follows: FEB (+ growth factors day 0) or BGAA (+ growth factors day 35) medium overnight; R, 50 nM rapamycin for 1.5 hr; starvation in Neurobasal medium (− growth factors) for 5 hr; IGF1 (10 ng/ml) (I) or BDNF (20 ng/ml) (B) for 30 min. DMSO was vehicle control in untreated cells. See also Figure S4.
**A** NSCs → Rapamycin 1w → Proliferation → Differentiation → Maturation (Excitability / Excitatory synapse transmission)

**B**

**Day 7**

- Cell density

**Day 56**

- Soma size (µm²)

- HuC/D+ cells, % of total

**C**

- Input resistance [MΩ]

**D**

- TSC2+/+
- TSC2+/-
- TSC2-/-
- TSC2+/- Rap 1w
- TSC2-/- Rap 7w

**E**

- AP firing (Hz)

**F**

- sEPSCs

**G**

- Gabazine

**H**

- mEPSCs

**I**

- TTX + gabazine

**J**

- TSC2+/+
- TSC2-/-
- TSC2-/- Rap 7w

**K**

- Amplitude (pA)

**L**

- Decay (ms)

(legend on next page)
TSC2+/− NSCs during the first 7 days of differentiation reverted cell density and soma size to control levels but failed to correct the deficit in neuronal differentiation (Figures 4A and 4B). The latter phenotype was partially ameliorated when the treatment was applied on proliferating NSCs during the patterning stage, suggesting that earlier application of rapamycin during neuroectodermal differentiation might be beneficial (Figure S4I).

In mature neurons, whole-cell patch-clamp recordings revealed that TSC2+/− neurons had an ~50% reduction in electrical input resistance and an ~2-fold increase in membrane capacitance (Figures 4C and S4J), which correlated with increased total dendritic length of individual cells (Figure S4K). Normalizing the input conductance by the capacitance in individual cells revealed no significant differences between genotypes, indicating that the conductance density of open ion channels at the resting membrane potential was not significantly different (data not shown) and suggesting that the alterations in passive membrane properties are likely due to increased cell size. Since the increased capacitance and decreased input resistance might impact electrical excitability, we measured action potential (AP) firing in response to 1-s current pulses with increasing current amplitudes. While TSC2+/− neurons responded similarly to control cells, TSC2+/− neurons required a 2-fold-larger current amplitude to generate the same frequency of AP firing (Figures 4D and 4E). Similar results were obtained when measuring the AP firing probability in response to brief 10-ms current pulses with increasing amplitude (Figures S4L and S4M). The functional properties of voltage-gated sodium and potassium channels were unlikely to be different, since the shapes of individual APs were indistinguishable across genotypes (Figures S4N–S4P). To test whether changes in electrical excitability were due to enhanced mTORC1 activity, we treated cells for 7 weeks with 2 nM rapamycin, a concentration that inhibits mTORC1 signaling (Figures S4G), starting at day 7, after early neuronal differentiation had occurred. Remarkably, after treatment, both passive membrane properties and AP firing were indistinguishable from control (Figures 4C–4E, S4J, and S4L).

Our molecular analysis suggested alterations in excitatory synaptic function in TSC2+/− and TSC2+/− neurons (Figure 2I). To analyze glutamatergic synapse formation and excitatory synaptic transmission, we recorded spontaneous excitatory synaptic currents (sEPSCs) and miniature excitatory synaptic currents (mEPSCs) in the presence of the GABA<sub>A</sub>-receptor antagonist gabazine (4 μM). The frequency of sEPSCs (0.57 ± 0.15 Hz, n = 12, control) was significantly reduced in TSC2+/− as well as in TSC2+/− neurons relative to control lines in a gene-dosage-dependent manner (0.28 ± 0.05 Hz, p < 0.05, n = 24 and 0.16 ± 0.04 Hz, p < 0.01, n = 11, respectively; Figures 4F and 4G). The phenotype was reverted by long-term (7 weeks starting at day 7 of differentiation), but not acute (2 hr starting at 8 weeks of differentiation), treatment with rapamycin. To understand whether the phenotype could be rescued at late developmental stage by long-term treatment, we applied rapamycin for 3–4 weeks starting at 6 weeks of differentiation. The treatment fully corrected the deficit in sEPSCs frequency (TSC2+/− with 3- to 4-week rapamycin: 0.69 ± 0.22 Hz, n = 7). To test whether the reduction in frequency of sEPSCs was caused by decreased excitability or a reduced number of synaptic connections, we recorded mEPSCs in the presence of 0.5 μM TTX. Similarly to spontaneous synaptic currents, mEPSC frequency (0.15 ± 0.04 Hz, n = 24) was reduced in mutant neurons (TSC2+/−: 0.04 ± 0.02 Hz, n = 7; TSC2+/−: 0.01 ± 0.01, n = 11), indicating a reduced number of glutamatergic synapses, and the phenotype was corrected by chronic rapamycin treatment (Figures 4H and 4I). Furthermore, rapamycin could correct the slight but significant increase in the amplitude and decay time course of average mEPSCs in TSC2+/− neurons (Figures 4J–4L).

Taken together, these data show that neuronal and synaptic alterations, including a deficit in glutamatergic synaptic transmission, are triggered in a TSC2-gene-dosage-dependent manner and can be corrected by pharmacological mTORC1 inhibition. Importantly, synaptic defects are corrected even when rapamycin treatment is started after the establishment of synaptic network connectivity.

**Figure 4. Reversal of Neurodevelopmental and Synaptogenesis Deficits by mTORC1 Inhibition**

(A) Outline of phenotypic reversal experiments with rapamycin treatment. NSCs, neural stem cells.
(B) Cell density (DAPI+ nuclei/field), neuronal soma size (HuC/D+ area), and neuronal content (% of HuC/D+ cells / DAPI+ nuclei). Data represent mean ± SEM. Untreated: ten wells/plate, 27 fields/well, four plates; treated: three wells, 27 fields/well. ***p < 0.001, **p < 0.01, *p < 0.05.
(C) Input resistance of day 56–63 differentiated neurons untreated or treated with 2 nM rapamycin for 7 weeks. TSC2+/−: n = 37, TSC2+/−: untreated n = 39, treated n = 4; TSC2+/−: untreated n = 31, treated n = 27.
(D) Representative recordings of action potentials (AP) induced by somatic current injections of 18 and 28 pA.
(E) AP firing frequency-current relationship calculated from recordings of action potentials induced by a 1-s pulse of somatic current injections I = 2 pA. Curve was constructed using Boltzmann sigmoidal fit in GraphPad Prism.
(F) Frequency of spontaneous EPSCs (5-min recording in the presence of 4 μM gabazine). TSC2+/−: n = 12; TSC2+/−: untreated n = 24, treated for 2 hr with 20 nM rapamycin n = 12, treated with 2 nM rapamycin for 3–4 weeks n = 7 or for 7 weeks n = 12; TSC2+/−: untreated n = 11, treated with 2 nM rapamycin for 7 weeks n = 10.
(G) Representative traces of sEPSCs quantified in (F).
(H) Frequency of mEPSC in day 56–63 differentiated neurons untreated or treated with 2 nM rapamycin for 7 weeks. TSC2+/−: n = 24; TSC2+/−: untreated n = 7, treated n = 5; TSC2+/−: untreated n = 11, treated n = 12.
(I) Representative traces of mEPSCs quantified in (H) recorded in the presence of 0.5 μM TTX and 4 μM gabazine.
(J) Representative traces of mEPSCs. Black line represents the average of 25 single events. Gray line represents the biexponential fit of the average trace.
(K) Amplitudes of mEPSCs in neurons untreated or treated with 2 nM rapamycin for 7 weeks. TSC2+/−: n = 18; TSC2+/−: untreated n = 5, treated n = 4; TSC2+/−: untreated n = 5, treated n = 6.
(L) Decay time constants of mEPSCs in neurons untreated or treated with 2 nM rapamycin for 7 weeks. TSC2+/−: n = 18; TSC2+/−: untreated n = 5, treated n = 4; TSC2+/−: untreated n = 5, treated n = 6.

Bar graphs represent mean ± SEM (C, E, F, H, K, and L); *p < 0.05; **p < 0.01. See also Figure S4.
DISCUSSION

The pathophysiological mechanisms underlying neuroanatomical and neurological alterations in patients affected by TSC are largely unknown. Here, we show that TSC2 deletion leads to exaggerated mTORC1 signaling during differentiation of human neurons in a gene-dosage-dependent manner, and this correlates with molecular and cellular alterations at multiple developmental stages. We show that TSC2 deletion alters the structure of human neuroectodermal rosettes, providing an in vitro correlate of neural tube formation deficits observed during in vivo embryonic development. Interestingly, abnormal rosette organization has been recently reported in hiPSCs carrying 15q11.2 microdeletion, a risk factor for schizophrenia and autism, supporting a role for early neurodevelopmental defects in neuropsychiatric disorders (Yoon et al., 2014). At later stages, we show that heterozygous loss of TSC2 results in a transient delay in early neuronal differentiation. Deficits in neuronal differentiation have been suggested to lead to abnormal brain wiring and could contribute to the altered connectivity observed in TSC patients (Krishnan et al., 2010; La Fata et al., 2014; Baumer et al., 2015). Furthermore, we demonstrate that heterozygous and homoygous loss of TSC2 leads to altered synaptogenesis and transmission. By inhibiting mTORC1 at different developmental stages, we show that early neurodevelopment and synaptogenesis can be uncoupled and corrected independently of each other. Indeed, excitatory synapse development can be corrected in both genotypes by long-term mTORC1 inhibition even after the onset of early differentiation deficits. Importantly, the correction is achieved even when the treatment is started at late differentiation stages, after synaptic network connectivity has been established.

Cortical tubers are a common neuropathological feature in TSC patients and their role in epilepsy and cognitive impairment is under close scrutiny (Jansen et al., 2007, 2008; Doherty et al., 2005; Major et al., 2009). We show that homozygous deletion of TSC2 recapitulates molecular, cellular, and electrophysiological features observed in dysplastic neurons from cortical tubers. Notably, alterations are dependent on mTORC1-hyperactivity, as they can be corrected by rapamycin treatment. Extending the functional characterization of our TSC2 mutant neurons will contribute to understand the role of altered mTORC1 signaling, excitability, and synaptic connectivity in the onset of neuronal network dysfunction and of epilepsy, a pathological feature associated with TSC and involved in the development of ASD.

Patients affected by TSC present with autism (50%) and comorbid symptoms including epilepsy (80%–90%) and varying degrees of intellectual disability (45%) (Jeste et al., 2008; Crino et al., 2006; Curatolo and Bombardieri, 2008). ASD is characterized by a remarkable heterogeneity in genetic causes and clinical manifestations. Consequently, identifying convergence in ASD biology remains an elusive challenge. Using TSC as a model of monogenic forms of ASD, we have characterized phenotypes in human neurons including deficits in synaptogenesis and alterations in pathways and genes previously associated with ASD. Extending this analysis to multiple genetically defined models of ASD will provide an unprecedented opportunity to link human genetics to neuronal phenotypes and potentially identify shared pathophysiological mechanisms.

EXPERIMENTAL PROCEDURES

Genome Editing

Plasmids encoding zinc-finger nucleases (ZFNs) targeting exon 11 of TSC2 (CompoZr knockout ZFN) and mRNA encoding ZFNs targeting exon 1 of the PPP1R12C locus (CompoZr Targeted Integration Kit) were from Sigma. Targeting constructs harboring a loxp-flanked PGK promoter-driven neomycin phosphotransferase cassette surrounded by sequences homologous to the genomic locus adjacent to the ZFN cut sites were synthesized de novo. Constructs were electroporated into SA001 hESCs, which were selected with 0.2 μg/ml G418 (Life Technologies), and clones with site-specific cassette insertions were identified by PCRs from genomic DNA. For more detail, refer to Supplemental Experimental Procedures.

Neuronal Differentiation

For patterning, NSCs were plated on polyornithine/laminin-coated dishes at 10,000–15,000 cells/cm² in basal medium with 100 ng/ml FGF-8 (Peprotech), 200 ng/ml sonic hedgehog (Peprotech), and 100 μM ascorbic acid 2-phosphate (Sigma) and cultured for 1 week. For differentiation, the resultant progenitors were plated at 35,000–50,000 cells/cm² in basal medium with 20 ng/ml BDNF, 10 ng/ml glial cell-derived neurotrophic factor (GDNF; Peprotech), 500 μM dibutyryl cyclic AMP (Sigma), and 100 μM ascorbic acid 2-phosphate. For more detail, refer to Supplemental Experimental Procedures.

Electrophysiology

Recordings were performed at 22–24°C. Cells were superfused with ACSF containing (in mM): 123 NaCl, 25 D-Glucose, 10 HEPES, 25 NaHCO₃, 5 KCl, 1 NaH₂PO₄, 2 CaCl₂ and 1 MgCl₂. Internal solution contained (in mM): 140 KCl, 10 EGTA, 2 MgCl₂, 2 Na₂ATP, 1 Phosphocreatine and 0.3 NaGTP with a pH of 7.28. Gluconate-based solution contained 135 mM K-glucuronate, 20 mM KCl, 10 mM HEPES, 0.1 mM EGTA, 2 mM MgCl₂, 2 mM Na₂ATP, 1 mM phosphocreatine, and 0.3 mM NaGTP. Borosilicate glass patch pipettes (2.5–4.0 MΩ) were used. Cells were patched in the whole-cell configuration with a stable series resistance of Rₛ < 20 MΩ.

Imaging

Fluorescent images were acquired using a Leica TCS SP5 (Leica Microsystems) inverted microscope, Opera High Content Screening System (PerkinElmer) or Operetta High Content Imaging System (PerkinElmer). For data analysis, refer to Supplemental Experimental Procedures.

Western Blot

Protein samples were resolved on NuPAGE 4–12% gels and transferred to nitrocellulose membranes using the iBlot Dry Blotting System (Life Technologies). Blot scans were acquired using a Li-COR scanner (Odyssey) and analyzed using the Image Studio Software (Li-COR Biosciences). Antibodies are listed in Supplemental Experimental Procedures.

Transcriptome Analysis

Real-time qPCR was performed with TaqMan Gene Expression assays (Life Technologies) using a 96.96 Dynamic Array (Fluidigm). For data analysis, refer to Supplemental Experimental Procedures.

Mass Spectrometry

Experiments and peak selection were performed as described previously (Curkley et al., 2015). For data analysis, refer to Supplemental Experimental Procedures.
Supplemental Information includes Supplemental Experimental Procedures, four figures, and two tables and can be found with this article online at http://dx.doi.org/10.1016/j.celrep.2016.02.090.

AUTHOR CONTRIBUTIONS

V.C., S.A., and M.V. designed, conducted, and analyzed experiments and wrote the manuscript. V.C. performed cellular and molecular analyses. S.A. generated genome-edited lines and performed cellular and molecular analyses. M.V. and K.B. performed all the electrophysiological analyses and the biocytin-based morphological analysis. E.S., A.F., T.D., S.Z., S.L., C.P., L.C.-G., M.B., and A.K. performed experiments and analyzed data. M.E., C.M., F.K., P.P., and F.F. analyzed data. M.G., S.J., and A.G. provided scientific and experimental input. J.B. and R.J. designed the study, analyzed data, and wrote the manuscript.

CONFLICTS OF INTEREST


ACKNOWLEDGMENTS

We thank Isabell Spindler, Eva Hofmann, Inga Claussen, Rachel Haab, Camille Viviani, Jens Lamerz, Martine Schwager, and Carlo Cusulin for technical assistance and critical input. We thank Will Spooren and Johannes Mestbacher for valuable discussions. We thank Max Igelis for artwork. This work was supported by EU-AIMS as part of the Innovative Medicines Initiative Joint Under-taking under grant agreement 115300, the resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP7/2007-2013), the EFPIA companies in kind contribution, and Autism Speaks. V.C., S.A., M.V., and S.L. were supported by the Roche Post-doctoral Fellowship Program.

Received: October 20, 2015
Revised: January 23, 2016
Accepted: February 25, 2016
Published: March 24, 2016

REFERENCES


